Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
Backed by €19 million in EU funding, the initiative, called [email protected], will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
The Swedish firm will use its CETSA technology to profile the effects of a drug on up to 6,000 proteins from patient blood samples.
The SEK4.9 million ($585,000) grant will support development studies for the firm's Immray PanCan-d blood based test for the early detection of pancreatic cancer.
The firm's CEO said that its assay is applicable in other indications where immunosuppressive therapies are used, such as rheumatoid arthritis.
The company received a $1.2 million loan to support its American subsidiary, and a $294,000 grant to help pay for a new R&D facility in the Walloon region of Belgium.
The platform will combine electronic health record technologies with clinical decision support tools to enable physicians to personalize cancer screening decisions.
The firm said that the test may be validated as a prognostic test for colorectal cancer and a predictive test for cancer immunotherapies.
The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.